Molecular actors in Alzheimer's disease: Which diagnostic and therapeutic consequences?;Comment les acteurs moléculaires de la pathologie Alzheimer permettent de comprendre la démence ? Quelles conséquences diagnostiques et thérapeutiques ?

Therapie

Volumn 65, Issue 5, 2010, Pages 401-407

  Buée, Luc ^a,b,c   Blum, David ^a,b   Bombois, Stéphanie ^b,c   Buée Scherrer, Valérie ^a,b   Caillet Boudin, Marie Laure ^a,b   Colin, Morvane ^a,b   Deramecourt, Vincent ^a,b,c   Dhaenens, Claire Marie ^a,b,c   Galas, Marie Christine ^a,b   Hamdane, Malika ^a,b   Humez, Sandrine ^a,b   Maurage, Claude Alain ^a,b,c   Pasquier, Florence ^b,c   Sablonnière, Bernard ^a,b,c   Schraen Maschke, Susanna ^a,b,c   Sergeant, Nicolas ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Amyloids; Diagnosis; Tau; Therapy

Indexed keywords

AMYLOID PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DIAGNOSTIC PROCEDURE; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; ANIMAL; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; NEUROFIBRILLARY TANGLES;

EID: 79953737218     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010054     Document Type: Article

References (32)

1. Expertise collective: Maladie d'Alzheimer - Enjeux scientifiques, médicaux et sociétaux. Expertise Collective c- Les éditions Inserm, 2007 Paris. ISBN 9782-85598-858-6. http://ist.inserm.fr/basisrapports/ alzheimer.html.
2. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492-8.
3. Grossman M, Koenig P, Glosser G, et al. Neural basis for semantic memory difficulty in Alzheimer's disease: an fMRI study. Brain 2003; 126: 292-311. (Pubitemid 36172737)
4. Sleegers K, Lambert JC, Bertram L, et al. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010; 26: 84-93.
5. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984; 120: 885-90. (Pubitemid 14104991)
6. Masters CL, Simons G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer's disease and down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9. (Pubitemid 15053619)
7. Hannequin D, Campion D, Dumanchin C, et al. La génétique de la maladie d'Alzheimer. Rev Neurol (Paris) 1998; 154: S65-74.
8. Checler F, Buée L. Données fondamentales sur les pathologies amyloïde et tau: quelles perspectives thérapeutiques ? Ann Pharm Fr 2009; 67: 136-53.
9. Selkoe DJ. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 2001; 81: 741-66. (Pubitemid 32267077)
10. Nalivaeva NN, Fisk LR, Belyaev ND, et al. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 212-24. (Pubitemid 351536346)
11. Brion JP, Passareiro H, Nunez J, et al. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol (Bruxelles) 1985; 95: 229-35. (Pubitemid 15000733)
12. Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 2005; 1739(2-3): 179-97. (Pubitemid 40018537)
13. Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008; 5(2): 207-24. (Pubitemid 351670926)
14. Buée-Scherrer V, Hof PR, Buée L, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol 1996; 91: 351-9. (Pubitemid 26088970)
15. Buée-Scherrer V, Buée L, Leveugle B, et al. Pathological tau proteins in postencephalitic parkinsonism: comparison to Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997; 42: 356-9. (Pubitemid 27391119)
16. Buée-Scherrer V, Buée L, Hof PR, et al. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: immunochemical characterization of tau proteins. Am J Pathol 1995; 146: 924-32.
17. Vermersch P, Sergeant N, Ruchoux MM, et al. Specific tau variants in the brains of patients with myotonic dystrophy. Neurology 1996; 47(3): 711-7. (Pubitemid 26307302)
18. Delacourte A, Robitaille Y, Sergeant N, et al. Specific pathological tau protein variants characterize Pick's disease. J Neuropathol Exp Neurol 1996; 55: 159-68.
19. Buée L, Bussière T, Buée-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000; 33: 95-130.
20. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9(7): 532-44. (Pubitemid 351873467)
21. Burnouf S, Belarbi K, Fernandez-Gomez FJ, et al. Effects of long-lasting voluntary exercise in the THY-Tau22 transgenic mouse model of Alzheimer's disease-like tau pathology. Soc Neurosci Abstr 2009; 826-11 http://www. abstractsonline.com/Plan/ViewAbstract.aspx?mID=2285&sKey= ba6a6fa9-7f3d-4f65-830f-b36a1e439496&cKey=6e536e50-4ec7-4bfd-b0f3- 17fa8ba9e3cd&mKey=%7b081F7976-E4CD-4F3D-A0AF-E8387992A658%7d.
22. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65. (Pubitemid 29177915)
23. Delacourte A, Sergeant N, Champain D, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002; 59: 398-407. (Pubitemid 34857933)
24. Schraen-Maschke S, Dhaenens CM, Bombois S, et al. Les marqueurs biologiques de la maladie d'Alzheimer: quel intérêt pour un diagnostic moins tardif ? Rev Neurol (Paris) 2009; 165 Spec No 2: F97-103.
25. Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma Aß with risk of dementia: the prospective 3C-study. Neurology 2009; 73: 847- 53.
26. Sapra M, Kim KY. Anti-amyloid treatments in Alzheimer's disease. Recent Pat CNS Drug Discov 2009; 4(2): 143-8.
27. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009; 13(6): 550-7.
28. Schenk D. Treatment of Alzheimer's disease: the beginning of a new era. Curr Alzheimer Res 2006; 3: 177.
29. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous Tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-4. (Pubitemid 46717684)
30. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset Tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005; 102: 227-31. (Pubitemid 40094457)
31. Leroy K, Ando K, Héraud C, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant of transgenic mice with advanced neurofibrillary degeneration. J Alz Dis 2010; 19(2): 705-19.
32. http://www/taurx.com/pipeline-first.aspx.